Trevi Therapeutics reports positive Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis

Trevi Therapeutics, Inc.

Primary endpoint met: 25% of Haduvio subjects achieved 4-point WI-NRS reduction vs 14% placebo (p=0.0157).
Significant improvement in ItchyQoL (p=0.0002) and Prurigo Activity Scale (p=0.006) at week 14.
Safety profile consistent with prior trials; discontinuations 36.9% Haduvio vs 19.3% placebo.
Cash and investments expected ~$78M at June 30, 2022; plans to discuss data with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.